Healthy volunteers help check two zongertinib tablet versions
NCT ID NCT06360081
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed Phase 1 trial tested whether zongertinib tablets made by two different manufacturers are absorbed the same way in the body. Fifty-six healthy adults took a single dose of each version in random order. The goal was to compare drug levels in the blood to ensure the tablets are bioequivalent.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zongertinib
- What this could lead to
- If successful, this trial confirms that both versions of zongertinib are interchangeable, supporting reliable manufacturing for future treatments.
- What could go wrong
- This is an early-phase study in healthy volunteers, not patients. It only measures drug levels in the blood, not effectiveness against any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test